Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor vs. clopidogrel in patients undergoing implantation of paclitaxel-eluting stents in the femoropopliteal district: a randomized, nested pilot study using Frequency-Domain Optical Coherence Tomography (FD-OCT)

Trial Profile

Ticagrelor vs. clopidogrel in patients undergoing implantation of paclitaxel-eluting stents in the femoropopliteal district: a randomized, nested pilot study using Frequency-Domain Optical Coherence Tomography (FD-OCT)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Peripheral arterial disorders; Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2018 Primary endpoint (Net percentage volume obstruction assessed by Frequency-Domain -Optical Coherence Tomography) has not been met, according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2018 Status changed from recruiting to completed according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top